Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 19;14(24):5400.
doi: 10.3390/nu14245400.

Dp-ucMGP as a Biomarker in Sarcopenia

Natascha Schweighofer  1   2 , Christoph W Haudum  1   2 , Olivia Trummer  1 , Alice Lind  1 , Ewald Kolesnik  3 , Ines Mursic  1 , Albrecht Schmidt  3 , Daniel Scherr  3 , Andreas Zirlik  3 , Thomas R Pieber  1   2 , Nicolas Verheyen  3 , Barbara Obermayer-Pietsch  1
Affiliations

Dp-ucMGP as a Biomarker in Sarcopenia

Natascha Schweighofer et al. Nutrients. .

Abstract

Sarcopenia is linked with an increased risk of falls, osteoporosis and mortality and is an increasing problem for healthcare systems. No satisfying biomarkers for sarcopenia diagnosis exist, connecting bone, fat and muscle. Matrix-GLA-protein (MGP) is an adipokine that regulates bone metabolism and is associated with decreased muscle strength. Associations of dp-ucMGP were analyzed in the BioPersMed cohort (58 ± 9 years), including 1022 asymptomatic subjects at moderate cardiovascular risk. Serum measurements of dp-ucMGP in 760 persons were performed with the InaKtif MGP Kit with the IDS-iSYS Multi-Discipline Automated System. DXA data (792 persons) measured with the Lunar iDXA system and physical performance data (786 persons) were available. Dp-ucMGP plasma levels correlate with sarcopenia parameters like gait speed (ρ = −0.192, p < 0.001), appendicular skeletal muscle mass (ρ = 0.102, p = 0.005) and appendicular skeletal muscle mass index (ρ = 0.112, p = 0.001). They are lower in persons with sarcopenia (p < 0.001) and higher in persons with reduced physical performance (p = 0.019). Persons in the lowest dp-ucMGP quartile have the highest risk for reduced muscle mass, decreasing with each quartile, whereas persons in the highest quartile have the highest risk of reduced muscle strength. Dp-ucMGP might be a good biomarker candidate in sarcopenia characterization.

Keywords: BioPersMed cohort; biomarker; dp-ucMGP; sarcopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of available measurements in the BioPersMed study participants: PP: physical performance; HGS: handgrip strength; DXA: energy X-ray absorptiometry; dp-ucMGP: dephosphorylated, uncarboxylated matrix-GLA-protein; n: number.
Figure 2
Figure 2
Dp-ucMGP levels in persons with and without reduced muscle mass or physical performance. Dark grey box plots represent the presence of decreased muscle mass or physical performance, whereas light grey boxes represent their absence. Dp-ucMGP: dephosphorylated, uncarboxylated Matrix-GLA-protein; pmol: picomol; L: liters, n: number; ASM: appendicular skeletal muscle mass; AMMI: appendicular skeletal muscle mass index; HGS: handgrip strength. Stars represent high extreme values and light or dark grey dots high potential outliers.
Figure 3
Figure 3
Circulating dp-ucMGP levels and correlations with sarcopenia-relevant parameters in all (A) and normal and overweight/obese (B) individuals. Correlation analysis between circulating dp-ucMGP and muscle parameters. Spearman’s rho (ρ) and p values are indicated. In all individuals, the 95% confidence interval is indicated by light grey lines. HGS: handgrip strength; ASM: appendicular skeletal muscle mass; AMMI: appendicular skeletal muscle mass index; WHR: waist-to-hip ratio; BMI: body mass index; kg: kilogram; min: minutes, L: liter; nw: normal weight; ow: overweight; ob: obese.
Figure 4
Figure 4
Odds ratios with 95% confidence intervals for prevalent sarcopenia features according to dp-ucMGP quartiles in 700 study participants. Adjustment: age [years], alcohol consumption [drinks per week], smoking [pack years] and cardiorespiratory fitness. Boxes with darkening shades of grey represent the dp-ucMGP quartiles.
See this image and copyright information in PMC

References

    1. Morley J.E., Abbatecola A.M., Argiles J.M., Baracos V., Bauer J., Bhasin S., Cederholm T., Coats A.J.S., Cummings S.R., Evans W.J., et al. Sarcopenia with limited mobility: An international Consensus. J. Am. Med. Dir. Assoc. 2011;12:403–409. doi: 10.1016/j.jamda.2011.04.014. - DOI - PMC - PubMed
    1. dos Santos L., Cyrino E.S., Antunes M., Santos D.A., Sardinha L.B. Sarcopenia and physical independence in older adults: The independent and synergic role of muscle mass and muscle function. J. Cachexia Sarcopenia Muscle. 2016;8:245–250. doi: 10.1002/jcsm.12160. - DOI - PMC - PubMed
    1. Akune T., Muraki S., Oka H., Tanaka S., Kawaguchi H., Tokimura F., Yoshida H., Suzuki T., Nakamura K., Yoshimura N. Incidence of certified need of care in the long-term care insurance system and its risk factors in the elderly of Japanese population-based cohorts: The ROAD study. Geriatr. Gerontol. Int. 2013;14:695–701. doi: 10.1111/ggi.12155. - DOI - PubMed
    1. Steffl M., Bohannon Rw Sontakova L., Tufano J.J., Shiells K., Holmerova I. Relationship-between-sarcopenia-and-physical-activity-in-the. Clin. Interv. Aging. 2017;12:835–845. doi: 10.2147/CIA.S132940. - DOI - PMC - PubMed
    1. Beaudart C., Rizzoli R., Bruyère O., Reginster J.-Y., Biver E. Sarcopenia: Burden and challenges for public health. Arch. Public Health. 2014;72:45. doi: 10.1186/2049-3258-72-45. - DOI - PMC - PubMed

LinkOut - more resources